IGLVIVOR22-1

Across TCGA pan-cancer cohorts, IGLVIVOR22-1 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of IGLVIVOR22-1’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where IGLVIVOR22-1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types IGLVIVOR22-1 is over-expressed in tumor.

LUAD, COAD, and STAD are the cancer types where IGLVIVOR22-1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGLVIVOR22-1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	All	+0.227	<.001	7	view →
COAD	All	II,III,IV	+0.454	<.001	6	view →
STAD	All	All	+0.210	.006	6	view →
BLCA	All	All	+0.201	.015	6	view →
LUSC	All	All	+0.451	<.001	5	view →
PRAD	All	All	+0.538	<.001	2	view →
LIHC	All	All	+0.087	.012	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

IGLVIVOR22-1–LUAD

Open the LUAD breakdown →